ANZUP CLINICAL TRIAL UPDATES Throughout this year ANZUP has remained committed to continuing to work with our members, study chairs, sites and coordinating centres to help manage the impact COVID-19 has had on the conduct of our clinical trials. But we are pleased to report all trials have continued and a new trial was even opened. We launched our latest theranostic trial ENZA-p (ANZUP 1901). This randomised phase 2 trial aims to compare the effectiveness of enzalutamide in combination with Lutetium-177 PSMA, versus enzalutamide alone, for the treatment of prostate cancer. In addition, the UNICAB trial has taken on its first teletrial site at Goulburn Valley Hospital (Shepparton) under Border Medical Oncology (Albury). This marks an ANZUP first and we look forward to ever expanding the availability of our trials to rural and regional patients. We are also pleased to announce the DASL-HiCaP trial has opened its first international collaborative site with the inclusion of Auckland City Hospital in New Zealand. Thank you to all research teams and investigators for their efforts and to the participants for their involvement across all our trials.
ANZUP-led studies ENZA-p (ANZUP 1903)
BCG+MM (ANZUP 1301)
Study sites: 5
Study sites: 12
Recruitment: 13
Recruitment: 309
Target: 160 patients
Target: 500 patients
DASL-HiCAP (ANZUP 1801)
KEYPAD (ANZUP 1601)
Study sites: 22
Study sites: 15
Recruitment: 89
Recruitment: 42
Target: 1,100 patients across ANZ, US, Canada, UK and Ireland
Target: 70 patients
PCR MIB (ANZUP 1502)
P3BEP (ANZUP 1302)
Study sites: 6
Study sites: 25 ANZ
Recruitment: 24
Recruitment: 145
Target: 30 patients
Target: 500 patients
TIGER (ANZUP 1604)
UNICAB (ANZUP 1802)
Study sites: 4
Study sites: 11
Recruitment: 9
Recruitment: 17
Target: 60 ANZ and 420 patients internationally
Target: 48 patients
9 | ANZUP UPdate Summer 2020
As at 17 December 2020
